News articles about Coherus BioSciences (NASDAQ:CHRS) have trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Coherus BioSciences earned a news impact score of 0.25 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.9795135754339 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
NASDAQ:CHRS opened at $16.10 on Thursday. The company has a debt-to-equity ratio of -33.10, a current ratio of 4.06 and a quick ratio of 4.06. The stock has a market capitalization of $996.96 million, a PE ratio of -3.59 and a beta of 3.39. Coherus BioSciences has a one year low of $16.30 and a one year high of $16.50.
Coherus BioSciences (NASDAQ:CHRS) last posted its quarterly earnings data on Thursday, May 10th. The biotechnology company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.04). research analysts forecast that Coherus BioSciences will post -2.91 earnings per share for the current year.
Several equities research analysts have recently commented on CHRS shares. Maxim Group boosted their price target on shares of Coherus BioSciences from $18.00 to $22.00 and gave the company a “buy” rating in a report on Friday, May 11th. BidaskClub upgraded shares of Coherus BioSciences from a “hold” rating to a “buy” rating in a report on Tuesday, May 8th. Citigroup boosted their price target on shares of Coherus BioSciences from $23.00 to $25.00 and gave the company a “buy” rating in a report on Friday, March 9th. Zacks Investment Research upgraded shares of Coherus BioSciences from a “sell” rating to a “hold” rating in a report on Tuesday. Finally, ValuEngine upgraded shares of Coherus BioSciences from a “strong sell” rating to a “sell” rating in a report on Thursday, April 12th. One analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company’s stock. Coherus BioSciences currently has an average rating of “Buy” and an average target price of $30.11.
About Coherus BioSciences
Coherus BioSciences, Inc, a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis.
Receive News & Ratings for Coherus BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.